Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
62 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Brain Ischemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Brain Ischemia - Pipeline Review, H2 2014', provides an overview of the Brain Ischemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Brain Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Brain Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Brain Ischemia Overview 7 Therapeutics Development 8 Pipeline Products for Brain Ischemia - Overview 8 Pipeline Products for Brain Ischemia - Comparative Analysis 9 Brain Ischemia - Therapeutics under Development by Companies 10 Brain Ischemia - Therapeutics under Investigation by Universities/Institutes 12 Brain Ischemia - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Brain Ischemia - Products under Development by Companies 15 Brain Ischemia - Products under Investigation by Universities/Institutes 16 Brain Ischemia - Companies Involved in Therapeutics Development 17 Edge Therapeutics, Inc. 17 FibroGen, Inc. 18 Immune Pharmaceuticals, Inc. 19 Lixte Biotechnology Holdings, Inc. 20 Medestea Research & Production S.p.A. 21 NeuroNascent, Inc. 22 NeurOp, Inc 23 Spectrum Pharmaceuticals, Inc. 24 Sylentis S.A. 25 The International Biotechnology Center (IBC) �Generium� 26 Brain Ischemia - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 AB-002 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CIGB-845 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 EG-1962 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 F-573 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 FG-4497 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 GNR-014 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 IAC VITA - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 LB-100 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 LB-102 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 NP-10679 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecules for Brain Ischemia - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules for Brain Ischemia and Ischemic Stroke - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules to Activate Sigma Receptor for CNS Disorders - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 SPI-1620 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Stem Cell Therapy for Ischemia - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Brain Ischemia - Recent Pipeline Updates 56 Brain Ischemia - Dormant Projects 59 Brain Ischemia - Discontinued Products 60 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 62 Disclaimer 62
List of Tables Number of Products under Development for Brain Ischemia, H2 2014 8 Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Brain Ischemia - Pipeline by Edge Therapeutics, Inc., H2 2014 17 Brain Ischemia - Pipeline by FibroGen, Inc., H2 2014 18 Brain Ischemia - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 19 Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 20 Brain Ischemia - Pipeline by Medestea Research & Production S.p.A., H2 2014 21 Brain Ischemia - Pipeline by NeuroNascent, Inc., H2 2014 22 Brain Ischemia - Pipeline by NeurOp, Inc, H2 2014 23 Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 24 Brain Ischemia - Pipeline by Sylentis S.A., H2 2014 25 Brain Ischemia - Pipeline by The International Biotechnology Center (IBC) "Generium", H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Brain Ischemia Therapeutics - Recent Pipeline Updates, H2 2014 56 Brain Ischemia - Dormant Projects, H2 2014 59 Brain Ischemia - Discontinued Products, H2 2014 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.